摘要
依非韦伦(efavirenz)是中国HIV-1感染者广泛使用的一线抗HIV-1治疗药物。该药的临床标准用量来源于以白种人为主的临床试验,考虑到人种的差异、病理生理及合并用药的不同等对依非韦伦药物动力学的影响,标准剂量的依非韦伦并不适合所有的患者。本文综述依非韦伦血药浓度与其不良反应和疗效的相关性,依非韦伦相关代谢酶的基因多态性、利福平对其血药浓度的影响,并总结了有关中国HIV-1感染者使用依非韦伦的相关研究等,希望为临床及科研工作者提供参考。
Efavirenz is a first-line anti-HIV treatment drug and widely used in Chinese HIV-1 infected patients. The recommended standard dose of efavirenz is derived from clinical trials given priority to with Caucasian. The same dosage is not suitable for all patients considering the differences of race, pathology, physiology and drug combination, which affect the pharmacokinetic of efavirenz. This article reviews the relationship of efavirenz plasma concentration with adverse reactions and efficacy. The effect of genetic polymorphisms existing in related genes and rifampicin on efavirenz plasma concentration in Chinese HIV-1 infected patients are described as well.
出处
《世界临床药物》
CAS
2014年第5期264-271,共8页
World Clinical Drug
基金
十二五国家科技重大专项课题--成人艾滋病适宜治疗策略研究与应用(2012ZX10001003)
